| Literature DB >> 32156500 |
Zhongwei Xiong1, Lijia Chang2, Youge Qu2, Yaoyu Pu2, Siming Wang2, Yuko Fujita2, Tamaki Ishima2, Jincao Chen3, Kenji Hashimoto4.
Abstract
Although stroke is the most common acute cerebrovascular disease, there are no currently effective therapeutic drugs for ischemic stroke. (R,S)-ketamine has been shown to protect against brain injury in rodents after middle cerebral artery occlusion (MCAO). Interestingly, we reported that (R)-ketamine has greater beneficial effects than (S)-ketamine in animal models of depression and Parkinson's disease. This study was undertaken whether two enantiomers of ketamine show neuroprotective effects in MCAO model. MCAO-induced brain injury and behavioral abnormalities in mice was attenuated by subsequent administration of (R)-ketamine (10 mg/kg, twice, 1 and 24 h after MCAO), but not (S)-ketamine (10 mg/kg, twice, 1 and 24 h after MCAO). Furthermore, the treatment with (R)-ketamine (10 mg/kg, twice, 30 min before and 24 h after MCAO) significantly protected against brain injury and behavioral abnormalities in mice after MCAO. These findings suggest that (R)-ketamine can protect against neuronal injury and behavioral abnormalities in mice after MCAO. Therefore, it is likely that (R)-ketamine could represent a therapeutic drug for ischemic stroke.Entities:
Keywords: (R)-ketamine; (S)-ketamine; Ischemia; MCAO; Neuroprotection
Mesh:
Substances:
Year: 2020 PMID: 32156500 DOI: 10.1016/j.pbb.2020.172904
Source DB: PubMed Journal: Pharmacol Biochem Behav ISSN: 0091-3057 Impact factor: 3.533